Emergent BioSolutions to Release First Quarter 2022 Financial Results and Conduct Conference Call on April 28, 2022

Rhea-AI Summary

Emergent BioSolutions Inc. (NYSE: EBS) announced a conference call on April 28, 2022, at 5:00 PM ET to discuss its Q1 2022 financial results, recent business developments, and revenue guidance for Q2 2022 and the full year 2022.

Investors can participate via telephone or webcast. The toll-free dial-in number is (855) 766-6521, with a conference ID of 3691528. A replay will be available on the company’s website following the call.

GAITHERSBURG, Md., April 08, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 28, 2022, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2022, recent business developments, revenue guidance for the second quarter of 2022, and financial outlook for full year 2022.

This conference call can be accessed live by telephone or by webcast:

Teleconference Information:
Dial in number – toll-free: (855) 766-6521
Dial in number – toll: (262) 912-6157
Conference ID: 3691528

Webcast Information:
Visit https://edge.media-server.com/mmc/p/84272zeqfor the live webcast.

A replay of the call can be accessed from the Investors page of the Emergent website.

About Emergent BioSolutions
At Emergent, our mission is to protect and enhance life. For over 20 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our website and follow us on LinkedIn, Twitter, and Instagram.

Investor Contact:
Robert G. Burrows
Vice President, Investor Relations
240-631-3280
burrowsr@ebsi.com  

Media Contact:
Matt Hartwig
Senior Director, Media Relations
mediarelations@ebsi.com

 

FAQ

What are the financial results for Emergent BioSolutions for Q1 2022?

The Q1 2022 financial results will be discussed during the conference call on April 28, 2022.

What is Emergent BioSolutions' revenue guidance for Q2 2022?

The revenue guidance for the second quarter of 2022 will be provided during the conference call.

How can I access the conference call for Emergent BioSolutions?

The conference call can be accessed via telephone at (855) 766-6521 or through the webcast.

When will Emergent BioSolutions provide its financial outlook for 2022?

The financial outlook for the full year 2022 will be discussed on the conference call scheduled for April 28, 2022.